UBS Group
IMRX icon

UBS Group’s Immuneering IMRX Stock Holding History

UBS Group’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.24M Buy
448,857
+72,573
+19% +$367K ﹤0.01% 5021
2026
Q1 		$1.98M Buy
376,284
+185,951
+98% +$953K ﹤0.01% 4984
2025
Q4 		$1.25M Buy
190,333
+63,931
+51% +$410K ﹤0.01% 5390
2025
Q3 		$885K Buy
126,402
+121,329
+2,392% +$630K ﹤0.01% 5675
2025
Q2 		$17.1K Sell
5,073
-23,478
-82% -$40.2K ﹤0.01% 8544
2025
Q1 		$43.4K Sell
28,551
-23,942
-46% -$43.5K ﹤0.01% 7690
2024
Q4 		$115K Buy
52,493
+20,948
+66% +$43.4K ﹤0.01% 6782
2024
Q3 		$78.5K Buy
31,545
+24,492
+347% +$35.6K ﹤0.01% 6528
2024
Q2 		$9.03K Sell
7,053
-21,898
-76% -$36K ﹤0.01% 7765
2024
Q1 		$83.7K Buy
+28,951
New +$162K ﹤0.01% 6300
2023
Q2 		– Sell
-2,713
Closed -$26.3K – 9235
2023
Q1 		$26.3K Buy
+2,713
New +$15.4K ﹤0.01% 6882
2022
Q4 		– Sell
-105
Closed -$2K – 10912
2022
Q3 		$2K Sell
105
-1,296
-93% -$10.3K ﹤0.01% 9733
2022
Q2 		$8K Sell
1,401
-1,862
-57% -$9.93K ﹤0.01% 8312
2022
Q1 		$21K Buy
3,263
+1,643
+101% +$15.8K ﹤0.01% 7393
2021
Q4 		$26K Buy
1,620
+501
+45% +$12.2K ﹤0.01% 7539
2021
Q3 		$30K Buy
+1,119
New +$30.1K ﹤0.01% 6751

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

UBS Group's IMRX Position: Q2 2026 in Review

UBS Group increased its Immuneering (IMRX) stake by 19% in Q2 2026, buying an estimated $367K and bringing the position to 448,857 shares worth $2.24M. The position accounts for ﹤0.01% of the portfolio, ranked #5021.

UBS Group first reported a position in IMRX in Q3 2021 and has held it in 16 quarters since. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • UBS Group held 448,857 shares of Immuneering worth $2.24M as of Q2 2026.
  • UBS Group bought 72,573 Immuneering shares in Q2 2026, an estimated $367K.
  • Immuneering made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5021 holding.
  • UBS Group first reported a position in Immuneering in Q3 2021 and has held it in 16 quarters since.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.